

Refine Search

Search Results -

Term	Documents
TETRACYCLINE	29350
TETRACYCLINES	4951
(16 AND TETRACYCLINE).PGPB,USPT,USOC,EPAB,JPAB,DWPI.	9
(L16 AND TETRACYCLINE).PGPB,USPT,USOC,EPAB,JPAB,DWPI.	9

Database:

US Pre-Grant Publication Full-Text Database
 US Patents Full-Text Database
 US OCR Full-Text Database
 EPO Abstracts Database
 JPO Abstracts Database
 Derwent World Patents Index
 IBM Technical Disclosure Bulletins

LDL

Search:

L18

Refine Search

Recall Text

Clear

Interrupt

Search History

DATE: Friday, March 25, 2005 [Printable Copy](#) [Create Case](#)

Set
Name Query
 side by
 side

Hit
Count Set
 Name
 result set

DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; THES=ASSIGNEE; PLUR=YES; OP=ADJ

L18 L16 and tetracycline 9 L18

L17 L16 and adriamycin 3 L17

L16 cholesterol conjugates 87 L16

L15 L14 and @py<2002 91 L15

L14 cholesterol and adriamycin same liposome 186 L14

DB=PGPB,USPT; THES=ASSIGNEE; PLUR=YES; OP=ADJ

L13 L12 and conjugate 16 L13

L12 cholesterol same adriamycin 194 L12

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1647

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	SEP 01	New pricing for the Save Answers for SciFinder Wizard within STN Express with Discover!
NEWS	4	OCT 28	KOREAPAT now available on STN
NEWS	5	NOV 30	PHAR reloaded with additional data
NEWS	6	DEC 01	LISA now available on STN
NEWS	7	DEC 09	12 databases to be removed from STN on December 31, 2004
NEWS	8	DEC 15	MEDLINE update schedule for December 2004
NEWS	9	DEC 17	ELCOM reloaded; updating to resume; current-awareness alerts (SDIs) affected
NEWS	10	DEC 17	COMPUAB reloaded; updating to resume; current-awareness alerts (SDIs) affected
NEWS	11	DEC 17	SOLIDSTATE reloaded; updating to resume; current-awareness alerts (SDIs) affected
NEWS	12	DEC 17	CERAB reloaded; updating to resume; current-awareness alerts (SDIs) affected
NEWS	13	DEC 17	THREE NEW FIELDS ADDED TO IFIPAT/IFIUDB/IFICDB
NEWS	14	DEC 30	EPFULL: New patent full text database to be available on STN
NEWS	15	DEC 30	CAPLUS - PATENT COVERAGE EXPANDED
NEWS	16	JAN 03	No connect-hour charges in EPFULL during January and February 2005
NEWS	17	FEB 25	CA/CAPLUS - Russian Agency for Patents and Trademarks (ROSPATENT) added to list of core patent offices covered
NEWS	18	FEB 10	STN Patent Forums to be held in March 2005
NEWS	19	FEB 16	STN User Update to be held in conjunction with the 229th ACS National Meeting on March 13, 2005
NEWS	20	FEB 28	PATDPAFULL - New display fields provide for legal status data from INPADOC
NEWS	21	FEB 28	BABS - Current-awareness alerts (SDIs) available
NEWS	22	FEB 28	MEDLINE/LMEDLINE reloaded
NEWS	23	MAR 02	GBFULL: New full-text patent database on STN
NEWS	24	MAR 03	REGISTRY/ZREGISTRY - Sequence annotations enhanced
NEWS	25	MAR 03	MEDLINE file segment of TOXCENTER reloaded
NEWS	26	MAR 22	KOREAPAT now updated monthly; patent information enhanced
NEWS	27	MAR 22	Original IDE display format returns to REGISTRY/ZREGISTRY
NEWS	28	MAR 22	PATDPASPC - New patent database available
NEWS	29	MAR 22	REGISTRY/ZREGISTRY enhanced with experimental property tags
NEWS EXPRESS			JANUARY 10 CURRENT WINDOWS VERSION IS V7.01a, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 10 JANUARY 2005
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS INTER			General Internet Information
NEWS LOGIN			Welcome Banner and News Items
NEWS PHONE			Direct Dial and Telecommunication Network Access to STN
NEWS WWW			CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 07:56:14 ON 25 MAR 2005

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'CAPLUS' ENTERED AT 07:56:44 ON 25 MAR 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 25 Mar 2005 VOL 142 ISS 14

FILE LAST UPDATED: 24 Mar 2005 (20050324/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s adriamycin cholesterol conjugate

9939 ADRIAMYCIN

16 ADRIAMYCINS

9941 ADRIAMYCIN

(ADRIAMYCIN OR ADRIAMYCINS)

152831 CHOLESTEROL

755 CHOLESTEROLS

152985 CHOLESTEROL

(CHOLESTEROL OR CHOLESTEROLS)

60060 CONJUGATE

53041 CONJUGATES

92633 CONJUGATE

(CONJUGATE OR CONJUGATES)

L1 0 ADRIAMYCIN CHOLESTEROL CONJUGATE

(ADRIAMYCIN (W) CHOLESTEROL (W) CONJUGATE)

=> s tetracycline cholesterol conjugate

22527 TETRACYCLINE

4198 TETRACYCLINES

23768 TETRACYCLINE

(TETRACYCLINE OR TETRACYCLINES)

152831 CHOLESTEROL

755 CHOLESTEROLS
 152985 CHOLESTEROL
 (CHOLESTEROL OR CHOLESTEROLS)
 60060 CONJUGATE
 53041 CONJUGATES
 92633 CONJUGATE
 (CONJUGATE OR CONJUGATES)
 L2 0 TETRACYCLINE CHOLESTEROL CONJUGATE
 (TETRACYCLINE (W) CHOLESTEROL (W) CONJUGATE)

=> s cholesterol conjugates
 152831 CHOLESTEROL
 755 CHOLESTEROLS
 152985 CHOLESTEROL
 (CHOLESTEROL OR CHOLESTEROLS)
 53041 CONJUGATES
 L3 118 CHOLESTEROL CONJUGATES
 (CHOLESTEROL (W) CONJUGATES)

=> s adriamycin
 9939 ADRIAMYCIN
 16 ADRIAMYCINS
 L4 9941 ADRIAMYCIN
 (ADRIAMYCIN OR ADRIAMYCINS)

=> s L3 and L4
 L5 1 L3 AND L4

=> d l5 1 ibib,abs

L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2001:825186 CAPLUS
 DOCUMENT NUMBER: 137:98786
 TITLE: Application to cancer chemotherapy of supramolecular
 system
 AUTHOR(S): Ichinose, Katsuro; Yamamoto, Masayuki; Taniguchi,
 Ikuo; Akiyoshi, Kazunari; Sunamoto, Junzo; Kanematsu,
 Takashi
 CORPORATE SOURCE: Department of Surgery II, Nagasaki University School
 of Medicine, Nagasaki, 852-8501, Japan
 SOURCE: Biomedical Polymers and Polymer Therapeutics,
 [Proceedings of the International Symposium on
 Frontiers in Biomedical Polymers Including Polymer
 Therapeutics: From Laboratory to Clinical Practice],
 3rd, Biwa Lake, Japan, May 23-27, 1999 (2001), Meeting
 Date 1999, 33-36. Editor(s): Chiellini, Emo. Kluwer
 Academic/Plenum Publishers: New York, N. Y.
 CODEN: 69BZMR
 DOCUMENT TYPE: Conference
 LANGUAGE: English
 AB Cholesterol conjugated pullulan bearing galactose moiety was synthesized
 as a cell recognition element. The validity of Gal-CHP liposome enclosing
 Adriamycin (Gal/CHP Lip-ADM) was studied. The radio-labeled CHP
 Lip or Gal/CHP Lip were added to cultured AH66 rat liver cancer cells in
 vitro. Athymic mice, which AH66 were s.c. transplanted, were i.v.
 administered free ADM, conventional liposome enclosing. The highest
 concentration of ADM in the tumor was detected in the Gal/CHP Lip-ADM group,
 which exhibited a stronger in vivo anti-tumor effect. The validity of
 nanoparticles of Gal-CHP self-aggregation and neocarzinostatin chromophore
 (NCS-chr) complex (Gal-CHP/NCS-chr) as a drug carrier was also examined. The
 activity rate for Gal-CHP self-aggregation complex was higher than for CHP
 self-aggregation complex. Among athymic mice transplanted 3'-mRLh-2 in
 liver, mice injected Gal-CHP/NCS-chr showed the longest survival. These
 results suggested that CHP allows drug carriers to easily conjugate with

galactose moiety, thus resulting in the effective and selective targeting of anti-tumor drugs against cancer lesion.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 07:56:14 ON 25 MAR 2005)

FILE 'CAPLUS' ENTERED AT 07:56:44 ON 25 MAR 2005

L1 0 S ADRIAMYCIN CHOLESTEROL CONJUGATE
L2 0 S TETRACYCLINE CHOLESTEROL CONJUGATE
L3 118 S CHOLESTEROL CONJUGATES
L4 9941 S ADRIAMYCIN
L5 1 S L3 AND L4

=> s tetracycline

22527 TETRACYCLINE
4198 TETRACYCLINES
L6 23768 TETRACYCLINE
(TETRACYCLINE OR TETRACYCLINES)

=> s L3 and L6

L7 0 L3 AND L6

=> cholesterol conjugate and tetracycline and liposome

CHOLESTEROL IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s cholesterol conjugate and tetracycline and liposome

152831 CHOLESTEROL
755 CHOLESTEROLS
152985 CHOLESTEROL
(CHOLESTEROL OR CHOLESTEROLS)
60060 CONJUGATE
53041 CONJUGATES
92633 CONJUGATE
(CONJUGATE OR CONJUGATES)
133 CHOLESTEROL CONJUGATE
(CHOLESTEROL (W) CONJUGATE)
22527 TETRACYCLINE
4198 TETRACYCLINES
23768 TETRACYCLINE
(TETRACYCLINE OR TETRACYCLINES)
32083 LIPOSOME
39391 LIPOSOMES
45367 LIPOSOME
(LIPOSOME OR LIPOSOMES)
L8 0 CHOLESTEROL CONJUGATE AND TETRACYCLINE AND LIPOSOME

=> s LDL or liposome

28888 LDL
524 LDLS
28957 LDL
(LDL OR LDLS)
32083 LIPOSOME
39391 LIPOSOMES
45367 LIPOSOME
(LIPOSOME OR LIPOSOMES)
L9 73944 LDL OR LIPOSOME

=> s cholesterol conjugate
152831 CHOLESTEROL
755 CHOLESTEROLS
152985 CHOLESTEROL
(CHOLESTEROL OR CHOLESTEROLS)
60060 CONJUGATE
53041 CONJUGATES
92633 CONJUGATE
(CONJUGATE OR CONJUGATES)
L10 133 CHOLESTEROL CONJUGATE
(CHOLESTEROL(W) CONJUGATE)

=> s adriamycin or tetracycline
9939 ADRIAMYCIN
16 ADRIAMYCINS
9941 ADRIAMYCIN
(ADRIAMYCIN OR ADRIAMYCINS)
3 TERTRACYCLINE
1 TERTRACYCLINES
4 TERTRACYCLINE
(TERTRACYCLINE OR TERTRACYCLINES)
L11 9945 ADRIAMYCIN OR TERTRACYCLINE

=> d his

(FILE 'HOME' ENTERED AT 07:56:14 ON 25 MAR 2005)

FILE 'CAPLUS' ENTERED AT 07:56:44 ON 25 MAR 2005

L1 0 S ADRIAMYCIN CHOLESTEROL CONJUGATE
L2 0 S TETRACYCLINE CHOLESTEROL CONJUGATE
L3 118 S CHOLESTEROL CONJUGATES
L4 9941 S ADRIAMYCIN
L5 1 S L3 AND L4
L6 23768 S TETRACYCLINE
L7 0 S L3 AND L6
L8 0 S CHOLESTEROL CONJUGATE AND TETRACYCLINE AND LIPOSOME
L9 73944 S LDL OR LIPOSOME
L10 133 S CHOLESTEROL CONJUGATE
L11 9945 S ADRIAMYCIN OR TERTRACYCLINE

=> s L10 and L11
L12 1 L10 AND L11

=> d L12 1 ibib,abs

L12 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:825186 CAPLUS

DOCUMENT NUMBER: 137:98786

TITLE: Application to cancer chemotherapy of supramolecular system

AUTHOR(S): Ichinose, Katsuro; Yamamoto, Masayuki; Taniguchi, Ikuo; Akiyoshi, Kazunari; Sunamoto, Junzo; Kanematsu, Takashi

CORPORATE SOURCE: Department of Surgery II, Nagasaki University School of Medicine, Nagasaki, 852-8501, Japan

SOURCE: Biomedical Polymers and Polymer Therapeutics, [Proceedings of the International Symposium on Frontiers in Biomedical Polymers Including Polymer Therapeutics: From Laboratory to Clinical Practice], 3rd, Biwa Lake, Japan, May 23-27, 1999 (2001), Meeting Date 1999, 33-36. Editor(s): Chiellini, Emo. Kluwer Academic/Plenum Publishers: New York, N. Y.

CODEN: 69BZMR

DOCUMENT TYPE: Conference

LANGUAGE: English

AB Cholesterol conjugated pullulan bearing galactose moiety was synthesized as a cell recognition element. The validity of Gal-CHP liposome enclosing **Adriamycin** (Gal/CHP Lip-ADM) was studied. The radio-labeled CHP Lip or Gal/CHP Lip were added to cultured AH66 rat liver cancer cells in vitro. Athymic mice, which AH66 were s.c. transplanted, were i.v. administered free ADM, conventional liposome enclosing. The highest concentration of ADM in the tumor was detected in the Gal/CHP Lip-ADM group, which exhibited a stronger in vivo anti-tumor effect. The validity of nanoparticles of Gal-CHP self-aggregation and neocarzinostatin chromophore (NCS-chr) complex (Gal-CHP/NCS-chr) as a drug carrier was also examined. The activity rate for Gal-CHP self-aggregation complex was higher than for CHP self-aggregation complex. Among athymic mice transplanted 3'-mRLh-2 in liver, mice injected Gal-CHP/NCS-chr showed the longest survival. These results suggested that CHP allows drug carriers to easily conjugate with galactose moiety, thus resulting in the effective and selective targeting of anti-tumor drugs against cancer lesion.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> s cholesterol
152831 CHOLESTEROL
755 CHOLESTEROLS
L13 152985 CHOLESTEROL
(CHOLESTEROL OR CHOLESTEROLS)

=> s adriamycin
9939 ADRIAMYCIN
16 ADRIAMYCINS
L14 9941 ADRIAMYCIN
(ADRIAMYCIN OR ADRIAMYCINS)

=> s conjugate
60060 CONJUGATE
53041 CONJUGATES
L15 92633 CONJUGATE
(CONJUGATE OR CONJUGATES)

=> s L13 and L14 and L15
L16 13 L13 AND L14 AND L15

=> d L16 ibib,abs

L16 ANSWER 1 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2005:98999 CAPLUS
DOCUMENT NUMBER: 142:193953
TITLE: Triosephosphate isomerase directed diagnostics and
therapeutics for multidrug resistant neoplastic
disease
INVENTOR(S): Georges, Elias; Serfass, Lucile; Bonneau, Anne-Marie;
Dallaire, Frederic
PATENT ASSIGNEE(S): Aurelium Biopharma, Inc., Can.
SOURCE: U.S. Pat. Appl. Publ., 57 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005026231	A1	20050203	US 2004-801988	20040315
PRIORITY APPLN. INFO.:			US 2003-455005P	P 20030314

AB Disclosed are methods for detecting neoplastic or damaged cells and for detecting multidrug resistance in neoplastic or damaged cells by detecting an increase in the cellular expression of a triosephosphate isomerase (TPI) protein in a multidrug resistant neoplastic or damaged cells as compared to the level of expression of the triosephosphate isomerase protein in a normal cell. Cellular TPI-targeted agents are disclosed for treatment or prevention of such neoplasms. The invention is based, in part, upon the discovery that TPI, a normally intracellular protein, is expressed more abundantly in neoplastic cells and damaged cells than normal cells of the same cell type, and is expressed still more abundantly in multidrug resistant (MDR) neoplastic cells. Antibodies to TPI are useful in detecting and treating neoplasms. Vaccines contain TPI or fragment.

=> d his

(FILE 'HOME' ENTERED AT 07:56:14 ON 25 MAR 2005)

FILE 'CAPLUS' ENTERED AT 07:56:44 ON 25 MAR 2005

L1 0 S ADRIAMYCIN CHOLESTEROL CONJUGATE
L2 0 S TETRACYCLINE CHOLESTEROL CONJUGATE
L3 118 S CHOLESTEROL CONJUGATES
L4 9941 S ADRIAMYCIN
L5 1 S L3 AND L4
L6 23768 S TETRACYCLINE
L7 0 S L3 AND L6
L8 0 S CHOLESTEROL CONJUGATE AND TETRACYCLINE AND LIPOSOME
L9 73944 S LDL OR LIPOSOME
L10 133 S CHOLESTEROL CONJUGATE
L11 9945 S ADRIAMYCIN OR TERTRACYCLINE
L12 1 S L10 AND L11
L13 152985 S CHOLESTEROL
L14 9941 S ADRIAMYCIN
L15 92633 S CONJUGATE
L16 13 S L13 AND L14 AND L15

=> d L16 2-13 ibib,abs

L16 ANSWER 2 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:14184 CAPLUS

DOCUMENT NUMBER: 142:120497

TITLE: Combination liposomal formulations comprising phospholipids

INVENTOR(S): Jamil, Haris; Ahmad, Imran; Ahmad, Zafeer; Anyarambhatla, Gopal

PATENT ASSIGNEE(S): Neopharm, Inc., USA

SOURCE: PCT Int. Appl., 39 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005000266	A2	20050106	WO 2004-US16413	20040522
WO 2005000266	A3	20050217		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG

PRIORITY APPLN. INFO.:

US 2003-472664P P 20030522

US 2003-495260P P 20030813

AB The present invention provides a composition comprising a physiologically acceptable carrier and two or more agents encapsulated in a liposome, wherein the combination of the two or more agents possess the following properties: (1) cytotoxicity to tumor cells, (2) nutritional properties, (3) use in application to nails, hair, skin or lips, or (4) activity against parasites and insects. The invention also provides a method of making such a composition. The invention further provides a method of treating cancer when the combination of the two or more agents is cytotoxic to tumor cells. For example, an initial formulation of liposome-encapsulated paclitaxel (LEP) was prepared containing phosphatidylcholine, cholesterol and cardiolipin. Sucrose and tocopherol were added to the formulation as stabilizers in order to form a sterilized lyophilized cake. Either doxorubicin (0.5 to 1.5 mg/mL) or mitoxantrone (0.5 to 1.5 mg/mL) was dissolved in water, and the solution was employed to reconstitute the lyophilized LEP cakes. The drug to lipid ratio varied from 1:120 to 1:24 (weight/weight) for doxorubicin and 1:120 to 1:24 (weight/weight) for mitoxantrone. The reconstitution of the LEP cake with doxorubicin or mitoxantrone solution resulted in entrapment of either of the additive drugs (doxorubicin or mitoxantrone) into the liposomal formulation of paclitaxel (LEP). Moreover, 78 to 100% of the additive drug was entrapped into the LEP at a drug to lipid ratio of 1:120 to 1:15 for mitoxantrone and 1:120 to 1:24 for doxorubicin. Presence of an additional drug, doxorubicin or mitoxantrone, did not alter entrapment efficiency of paclitaxel in liposomes, size or stability of liposomes. Paclitaxel content remained intact after entrapping mitoxantrone or doxorubicin. This suggested that both drugs can coexist in a single delivery system without compromising size, entrapment efficiency or stability of the liposomal formulation.

L16 ANSWER 3 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:1036851 CAPLUS

DOCUMENT NUMBER: 142:696

TITLE: Synergistic treatment of cancer using immunomers in conjunction with chemotherapeutic agents

INVENTOR(S): Kandimalla, Ekambar R.; Agrawal, Sudhir; Wang, Daqin

PATENT ASSIGNEE(S): Hybridon, Inc., USA

SOURCE: PCT Int. Appl., 106 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004103301	A2	20041202	WO 2004-US15313	20040514
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005009773	A1	20050113	US 2004-846167	20040514

PRIORITY APPLN. INFO.: US 2003-471247P P 20030516
OTHER SOURCE(S): MARPAT 142:696

AB The invention discloses the therapeutic use of immunostimulatory oligonucleotides and/or immunomers in combination with chemotherapeutic agents to provide a synergistic therapeutic effect.

L16 ANSWER 4 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:903794 CAPLUS

DOCUMENT NUMBER: 136:58784

TITLE: Encapsulation of plasmid DNA (Lipogenes) and therapeutic agents with nuclear localization signal/fusogenic peptide **conjugates** into targeted liposome complexes

INVENTOR(S): Boulikas, Teni

PATENT ASSIGNEE(S): USA

SOURCE: PCT Int. Appl., 107 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001093836	A2	20011213	WO 2001-US18657	20010608
WO 2001093836	A3	20021003		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2411542	AA	20011213	CA 2001-2411542	20010608
EP 1292284	A2	20030319	EP 2001-942131	20010608
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
US 2003072794	A1	20030417	US 2001-876904	20010608
JP 2003535832	T2	20031202	JP 2002-501409	20010608
PRIORITY APPLN. INFO.:			US 2000-210925P	P 20000609
			WO 2001-US18657	W 20010608

AB A method is disclosed for encapsulating plasmids, oligonucleotides or neg.-charged drugs into liposomes having a different lipid composition between their inner and outer membrane bilayers and able to reach primary tumors and their metastases after i.v. injection to animals and humans. The formulation method includes complex formation between DNA with cationic lipid mols. and fusogenic/NLS peptide **conjugates** composed of a hydrophobic chain of about 10-20 amino acids and also containing four or more histidine residues or NLS at their one end. The encapsulated mols. display therapeutic efficacy in eradicating a variety of solid human tumors including but not limited to breast carcinoma and prostate carcinoma. Combination of the plasmids, oligonucleotides or neg.-charged drugs with other anti-neoplastic drugs (the pos.-charged cis-platin, doxorubicin) encapsulated into liposomes are of therapeutic value. Also of therapeutic value in cancer eradication are combinations of the encapsulated plasmids, oligonucleotides or neg.-charged drugs with HSV-tk plus encapsulated ganciclovir.

L16 ANSWER 5 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:825186 CAPLUS

DOCUMENT NUMBER: 137:98786

TITLE: Application to cancer chemotherapy of supramolecular

system
AUTHOR(S): Ichinose, Katsuro; Yamamoto, Masayuki; Taniguchi, Ikuo; Akiyoshi, Kazunari; Sunamoto, Junzo; Kanematsu, Takashi
CORPORATE SOURCE: Department of Surgery II, Nagasaki University School of Medicine, Nagasaki, 852-8501, Japan
SOURCE: Biomedical Polymers and Polymer Therapeutics, [Proceedings of the International Symposium on Frontiers in Biomedical Polymers Including Polymer Therapeutics: From Laboratory to Clinical Practice], 3rd, Biwa Lake, Japan, May 23-27, 1999 (2001), Meeting Date 1999, 33-36. Editor(s): Chiellini, Emo. Kluwer Academic/Plenum Publishers: New York, N. Y.
CODEN: 69BZMR
DOCUMENT TYPE: Conference
LANGUAGE: English

AB **Cholesterol** conjugated pullulan bearing galactose moiety was synthesized as a cell recognition element. The validity of Gal-CHP liposome enclosing **Adriamycin** (Gal/CHP Lip-ADM) was studied. The radio-labeled CHP Lip or Gal/CHP Lip were added to cultured AH66 rat liver cancer cells in vitro. Athymic mice, which AH66 were s.c. transplanted, were i.v. administered free ADM, conventional liposome enclosing. The highest concentration of ADM in the tumor was detected in the Gal/CHP Lip-ADM group, which exhibited a stronger in vivo anti-tumor effect. The validity of nanoparticles of Gal-CHP self-aggregation and neocarzinostatin chromophore (NCS-chr) complex (Gal-CHP/NCS-chr) as a drug carrier was also examined. The activity rate for Gal-CHP self-aggregation complex was higher than for CHP self-aggregation complex. Among athymic mice transplanted 3'-mRLh-2 in liver, mice injected Gal-CHP/NCS-chr showed the longest survival. These results suggested that CHP allows drug carriers to easily **conjugate** with galactose moiety, thus resulting in the effective and selective targeting of anti-tumor drugs against cancer lesion.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 6 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:625226 CAPLUS
DOCUMENT NUMBER: 136:406691
TITLE: Study on third-type immunoliposomes loaded drugs and targeting in vitro and in vivo
AUTHOR(S): Hou, Xipu; Zhang, Yufeng; Xie, Shusheng; Hu, Xin
CORPORATE SOURCE: School of Pharmaceutical Science, Peking University, Beijing, 100083, Peop. Rep. China
SOURCE: Yaoxue Xuebao (2001), 36(7), 539-542
CODEN: YHHPAL; ISSN: 0513-4870
PUBLISHER: Yaoxue Xuebao Bianjibu
DOCUMENT TYPE: Journal
LANGUAGE: Chinese

AB The third-type immunoliposome (IML) loaded anticancer drugs-**adriamycin** (ADM) was prepared from the **conjugate** of monoclonal antibody of human bladder cancer with PEG-COOH (polyethylene glycol carboxylic acid). The survival rate of the targeting EJ cells treated with IML-ADM (ADM = 45.45 $\mu\text{g mL}^{-1}$) was $4.3 \pm 1.0\%$, but $72\% \pm 6\%$ for non-targeting LOVO cells in vitro. The tumor weight in nude mice implanted by EJ cells was (39 \pm 25), (135 \pm 32), and (598 \pm 240) mg by treatment with IML-ADM, SSL-ADM (steric stable liposomes carried **Adriamycin**), and normal saline for 27 d, resp. The results showed that the immunoliposome-mediated targeting anticancer drug was a feasible way.

L16 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:470555 CAPLUS
DOCUMENT NUMBER: 136:221596

TITLE: Correlations between the rate of intracellular release of endocytosed liposomal doxorubicin and cytotoxicity as determined by a new assay

AUTHOR(S): Kirchmeier, Marc J.; Ishida, Tatsuhiko; Chevrette, Julie; Allen, Theresa M.

CORPORATE SOURCE: Department of Pharmacology, University of Alberta, Edmonton, AB, T6G 2H7, Can.

SOURCE: Journal of Liposome Research (2001), 11(1), 15-29
CODEN: JLREE7; ISSN: 0898-2104

PUBLISHER: Marcel Dekker, Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Previously, we showed that liposomes with surface-attached anti-CD19 were internalized into human B lymphoma cells through receptor-mediated endocytosis, resulting in improved anti-tumor efficacy. In order to further increase the efficacy of antineoplastic drug-containing liposomes, we have taken advantage of this internalization process by producing triggered release liposomes that rapidly release drug from the enzyme-rich, acidic environment of lysosomes. To analyze the effectiveness of these triggered-release formulations, we developed a nuclear accumulation assay for doxorubicin (DXR) that allows us to determine the rate of cytoplasmic drug delivery subsequent to drug release from the endosomal/lysosomal compartments by examining the rate of accumulation of drug in cellular nuclei. We demonstrate the usefulness of this assay by comparing the kinetics of cytoplasmic drug delivery for DXR-containing, pH-sensitive, triggered release liposomes vs. DXR-containing, non-sensitive, liposomal formulations. We see a significant correlation between the rate of nuclear accumulation of DXR and its in vitro cytotoxicity. This indicates that pH-sensitive formulations traffic drug to the cytoplasm and the nucleus significantly more rapidly than do non-sensitive formulations. We conclude that the development of triggered release liposomes is a promising strategy for further improving the therapeutic efficacy of liposomal antineoplastic drugs targeted selectively to cancer cells by surface-attached ligands that bind to internalizing epitopes.

REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 8 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:359780 CAPLUS

DOCUMENT NUMBER: 134:371773

TITLE: Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes

INVENTOR(S): Boulikas, Teni

PATENT ASSIGNEE(S): USA

SOURCE: PCT Int. Appl., 44 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001034130	A1	20010517	WO 2000-US29723	20001027
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
US 6511676	B1	20030128	US 1999-434345	19991105

CA 2358948	AA	20010517	CA 2000-2358948	20001027
EP 1156789	A1	20011128	EP 2000-972379	20001027
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2003513911	T2	20030415	JP 2001-536130	20001027
AU 777151	B2	20041007	AU 2001-11048	20001027
GR 1004168	B2	20030226	GR 2000-100384	20001103
GR 2000100384	A	20010731		
US 2003185879	A1	20031002	US 2003-350470	20030123
PRIORITY APPLN. INFO.:			US 1999-434345	A 19991105
			WO 2000-US29723	W 20001027

AB A method for encapsulating cisplatin and other pos.-charged drugs into liposomes having a different lipid composition between their inner and outer membrane bilayers is disclosed. The liposomes are able to reach primary tumors and their metastases after i.v. injection to animals and humans. The encapsulated cisplatin has a high therapeutic efficacy in eradicating a variety of solid human tumors including but not limited to breast carcinoma and prostate carcinoma. Combination of the encapsulated cisplatin with encapsulated doxorubicin or with other antineoplastic drugs are claimed to be of therapeutic value. Also of therapeutic value in cancer eradication are claimed to be combinations of encapsulated cisplatin with a number of anticancer genes including but not limited to p53, IL-2, IL-12, angiostatin, and oncostatin encapsulated into liposomes as well as combinations of encapsulated cisplatin with HSV-tk plus encapsulated ganciclovir. Liposomes were prepared by mixing cisplatin and dipalmitoylphosphatidyl glycerol at a 1:1 M ratio in 30% ethanol, 0.1 M Tris.HCl, pH = 7 to achieve about 5 mg/mL final cisplatin concentration, then heating at 50°. Therapeutic efficacy of the liposomes was shown in mice injected with human breast carcinoma.


REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 9 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2000:553451 CAPLUS
DOCUMENT NUMBER: 133:168385
TITLE: Metal macrocycles for two-step forms of radiotherapy
INVENTOR(S): Lawaczek, Rudiger; Platzek, Johannes; Raduchel, Bernd
PATENT ASSIGNEE(S): Schering Aktiengesellschaft, Germany
SOURCE: PCT Int. Appl., 22 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2000045857	A2	20000810	WO 2000-EP473	20000121
WO 2000045857	A3	20010405		
W: AE, AL, AU, BA, BB, BG, BR, CA, CN, CR, CU, CZ, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KP, KR, LC, LK, LR, LS, LT, LV, MA, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, SD, SG, SI, SK, SL, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
DE 19905094	C1	20001012	DE 1999-19905094	19990201
PRIORITY APPLN. INFO.:			DE 1999-19905094	A 19990201
OTHER SOURCE(S):	MARPAT 133:168385			

GI



AB The invention relates to the use of at least one physiol. compatible compound of general formula (I), wherein U represents -CH₂-CH(OH)-CH₂- or -CHR-CO-NH-(CH₂)_n-CO, with R = H or Me, and n = 1-10, and T represents a tumor-specific radical of biol. or synthetic origin, for producing preps. for neutron capture and photon activation therapy.

L16 ANSWER 10 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1999:247471 CAPLUS

DOCUMENT NUMBER: 131:134532

TITLE: Stealth monensin liposomes as a potentiator of **adriamycin** in cancer treatment

AUTHOR(S): Singh, Mandip; Ferdous, Abu J.; Jackson, Tanise L.

CORPORATE SOURCE: College of Pharmacy and Pharmaceutical Sciences, Florida A and M University, Tallahassee, FL, 32307-3800, USA

SOURCE: Journal of Controlled Release (1999), 59(1), 43-53
CODEN: JCREEC; ISSN: 0168-3659

PUBLISHER: Elsevier Science Ireland Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Small unilamellar stealth monensin liposomes (SMLs) were prepared from multilamellar liposomes (MLVs). The MLVs were prepared by using dipalmitoyl phosphatidylcholine (DPPC), **cholesterol**, distearoyl glycerophosphoethanolamine coupled to poly(ethylene glycol) (DSPE-PEG) and stearylamine in the molar ratio of 10:5:1.4:1.4 (32.8 mM total lipid). The encapsulation efficiencies of monensin in MLVs and small unilamellar vesicles (SUVs) was 6+10⁻⁶ and 10⁻⁷ M, resp. The stability of SMLs was studied at 4°C. The amount of leakage of monensin from SMLs was less than 20% after four weeks of storage. The in vitro release of monensin from SMLs in human serum was determined, and t_{1/2} was found to be 10 h. Pharmacokinetic studies on SMLs were carried out in BALB/c mice. More than 20% of SMLs remained in blood circulation after 24 h. SMLs increased the uptake of **adriamycin** (AM) in HL-60-resistant cells by more than two fold, compared to monensin in solution. SMLs potentiated the effect of AM against both sensitive and resistant HL-60 cells (six- and tenfold potentiation, resp.) and human LOVO tumor cells (four- and 200-fold potentiation, resp.). However, the highest potentiation was observed against resistant human breast tumor MCF7 cells, and was found to be 2400 times in comparison to AM alone. Transmission electron microscopic studies carried out with HL-60-resistant tumor cells incubated with SMLs showed that SMLs caused dilation of the golgi of tumor cells within 10 min. The dilation of golgi was reversible after reincubation of the cells in fresh medium. SMLs showed considerable potential as a potentiator in combination with AM in overcoming drug resistance.

REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 11 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1998:542992 CAPLUS
 DOCUMENT NUMBER: 129:160642
 TITLE: Tolerance and elimination of B-cells producing natural antibodies to galactosyl epitope expressed on xenograft tissue
 INVENTOR(S): Thall, Aron
 PATENT ASSIGNEE(S): Biotransplant, Inc., USA
 SOURCE: PCT Int. Appl., 66 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9833528	A2	19980806	WO 1998-US2103	19980205
WO 9833528	A3	19990211		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2279544	AA	19980806	CA 1998-2279544	19980205
AU 9863191	A1	19980825	AU 1998-63191	19980205
EP 969872	A2	20000112	EP 1998-907366	19980205
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2001518074	T2	20011009	JP 1998-533214	19980205
PRIORITY APPLN. INFO.: US 1997-795925 A 19970205				
WO 1998-US2103 W 19980205				

AB The invention provides methods and compns. for promoting in a first species a state of tolerance against Gal α 1,3Gal epitopes present on a xenograft from a second species, thereby preventing hyperacute rejection (HAR) of the xenograft. In a first aspect, the invention provides methods and tolerogenic compns. for inducing anergy in B-cells specific for the Gal α 1,3Gal epitope. In a second aspect, the invention provides methods and tolerogenic compns. for inducing apoptosis in B-cells. In a third aspect, the invention provides methods and compns. for the cytotoxic elimination of memory B-cells and T-cells.

L16 ANSWER 12 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1995:324110 CAPLUS
 DOCUMENT NUMBER: 122:103590
 TITLE: Preparation of monoclonal antibodies against ovarian carcinoma bearing chemical drugs entrapped in liposomes and the cytotoxic effects on carcinoma cells in vitro
 AUTHOR(S): Li, Wenjin; Qian, Henian; Nie, Songqing
 CORPORATE SOURCE: People's Hospital, Beijing Med. Univ., Beijing, Peop. Rep. China
 SOURCE: Beijing Yike Daxue Xuebao (1994), 26(3), 184-5, 199
 CODEN: BYDXEV; ISSN: 1000-1530
 PUBLISHER: Beijing Yike Daxue
 DOCUMENT TYPE: Journal
 LANGUAGE: Chinese

AB Monoclonal antibodies COC166-9 were prepared bearing **adriamycin** and cis-platinum entrapped in liposomes resp. as chemoimmunoliposomes MLA and MLP. In vitro growth inhibition of SKOV3 ovarian carcinoma cell lines by MLA and MLP were tested. The results showed that MLA had the same cytotoxic effects as single **adriamycin** in high concentration However,

MLA was much stronger than **adriamycin** in low concentration. There was no difference in the inhibiting effect on SKOV3 cells between MLP and cis-platinum. The SKOV3 cells were not sensitive either to MLP or cis-platinum.

L16 ANSWER 13 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1994:465435 CAPLUS

DOCUMENT NUMBER: 121:65435

TITLE: Biodistribution and antitumor effect of **adriamycin** encapsulated in long-circulating liposomes containing amphipathic polyethylene glycol or ganglioside GM1

AUTHOR(S): Maruyama, Kazuo; Okamoto, Aki; Ishida, Osamu; Kojima, Shuji; Suginaka, Akinori; Huang, Leaf; Iwatsuru, Motoharu

CORPORATE SOURCE: Fac. Pharm. Sci., Teikyo Univ., Sagamiko, 199-01, Japan

SOURCE: Journal of Liposome Research (1994) 701-23

CODEN: JLREE7; ISSN: 0898-2104

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Biodistribution and antitumor effect of **adriamycin** (ADM) encapsulated in liposomes with reduced uptake by reticuloendothelial system (RES) and prolonged circulation time were investigated in mice. Two different types of long-circulating liposomes, ganglioside GM1 (GM1)/distearoylphosphatidylcholine (DSPC) /**cholesterol** (CH) (0.13:1:1) and amphipathic polyethylene glycol (PEG)/DSPC/CH (0.13:1:1) were used. They were sized to 180-200 nm in mean diameter. In the case of amphipathic PEG, distearoylphosphatidylethanolamine (DSPE) derivs. of PEG with various mol. weight (1000-12,000 in mean mol. weight) were used. ADM was encapsulated by transmembrane pH gradient method. GM1/DSPC/CH liposome entrapped ADM with over 95% in trapping efficiency and its drug retention after incubation with 20% serum in PBS (pH 7.4) for 24 h was 92%. Similar results were obtained with liposomes containing amphipathic PEG with average mol. weight of 1000, 2000 and 3000. However, the liposomes containing high mol. weight PEG such as 5000 and 12,000 showed decreased trapping efficiency such as 82% and 60%, resp. ADM-GM1/DSPC/CH liposomes and ADM-PEG/DSPC/CH liposomes showed low uptake by RES and high blood concentration at 6 h after i.v. injection, compared with ADM-DSPC/CH liposomes. ADM-PEG1000/DSPC/CH liposomes showed the highest concentration in blood among all PEG-liposomes. ADM concns. associated with RES (liver and spleen) of ADM-PEG1000/DSPC/CH and ADM-GM1/DSPC/CH were lower than that of ADM-DSPC/CH over the entire 24-h period. The antitumor efficacy of liposomal ADM was estimated in the L1210 leukemia tumor-bearing mice. Free ADM or liposomal ADM was injected at a dose of 2.0 or 5.0 mg/kg one day after tumor cell inoculation. When treated at a dose of 2.0 mg/kg, liposomal ADM displayed antitumor effect similar to that of free drug. The administration of ADM-GM1/DSPC/CH or ADM-PEG1000/DSPC/CH liposomes at a dose of 5.0 mg/kg to tumor bearing mice induced prolonged survival with 100% survival rate for at least 60 days after treatment.

=> d his

(FILE 'HOME' ENTERED AT 07:56:14 ON 25 MAR 2005)

FILE 'CAPLUS' ENTERED AT 07:56:44 ON 25 MAR 2005

L1 0 S ADRIAMYCIN CHOLESTEROL CONJUGATE

L2 0 S TETRACYCLINE CHOLESTEROL CONJUGATE

L3 118 S CHOLESTEROL CONJUGATES

L4 9941 S ADRIAMYCIN
 L5 1 S L3 AND L4
 L6 23768 S TETRACYCLINE
 L7 0 S L3 AND L6
 L8 0 S CHOLESTEROL CONJUGATE AND TETRACYCLINE AND LIPOSOME
 L9 73944 S LDL OR LIPOSOME
 L10 133 S CHOLESTEROL CONJUGATE
 L11 9945 S ADRIAMYCIN OR TETRACYCLINE
 L12 1 S L10 AND L11
 L13 152985 S CHOLESTEROL
 L14 9941 S ADRIAMYCIN
 L15 92633 S CONJUGATE
 L16 13 S L13 AND L14 AND L15

=> s L13 and tetracycline and L15
 22527 TETRACYCLINE
 4198 TETRACYCLINES
 23768 TETRACYCLINE
 (TETRACYCLINE OR TETRACYCLINES)
 L17 2 L13 AND TETRACYCLINE AND L15

=> d L17 1-2 ibib,abs

L17 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 1992:147517 CAPLUS
 DOCUMENT NUMBER: 116:147517
 TITLE: Phencyclidine and phencyclidine metabolite assays,
 tracers, immunogens, antibodies and reagent kit
 INVENTOR(S): Dubler, Robert Edward; Frintner, Mary Pat; Grote,
 Jonathan; Hawksworth, David James; Nam, Daniel S.;
 Wray, Larry Kay; Hadley, Gregg Allen; Hopkins, Hal
 Dayton; Ungemach, Frank S.
 PATENT ASSIGNEE(S): Abbott Laboratories, USA
 SOURCE: Eur. Pat. Appl., 34 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 459387	A2	19911204	EP 1991-108674	19910528
EP 459387	A3	19920902		
EP 459387	B1	19950920		
R: AT, BE, CH, DE, ES, FR, GB, IT, LI, NL				
US 5155212	A	19921013	US 1990-529988	19900529
AU 9177272	A1	19911205	AU 1991-77272	19910522
AU 643524	B2	19931118		
CA 2043372	AA	19911130	CA 1991-2043372	19910528
AT 128241	E	19951015	AT 1991-108674	19910528
ES 2080188	T3	19960201	ES 1991-108674	19910528
JP 04235199	A2	19920824	JP 1991-125955	19910529
US 5407834	A	19950418	US 1992-831762	19920427
PRIORITY APPLN. INFO.:			US 1990-529988	A 19900529
			US 1986-866193	B2 19860521

OTHER SOURCE(S): MARPAT 116:147517

AB The present invention is directed to a fluorescence polarization assay for
 phenylcyclidine and phenylcyclidine derivs., to the various components
 needed for preparing and carrying out such an assay, and to methods of making
 these components. Specifically, tracers, immunogens and (monoclonal)
 antibodies are disclosed, as well as methods for making them, and a
 reagent kit containing them. The tracers and the immunogens are made from
 substituted phencyclidine compds. A fluorescein moiety is included in the

tracer, while a poly(amino acid) forms a part of the immunogen. The assay is conducted by measuring the degree of polarization retention of plane polarized light that has been passed through a sample containing antiserum and tracer. The assay has a high degree of specificity for phencyclidine and metabolites and analogs thereof, while minimizing mass reactivity to a host of other synthetic metabolites and naturally occurring compds.

L17 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1977:550600 CAPLUS

DOCUMENT NUMBER: 87:150600

TITLE: Effect of antibiotics on **cholesterol** metabolism [in rats] fed rations with differing protein levels

AUTHOR(S): Sheveleva, S. A.; Nesterin, M. F.; Narodetskaya, R. V.

CORPORATE SOURCE: Inst. Pitan., Moscow, USSR

SOURCE: Voprosy Pitaniya (1977), (4), 17-21

CODEN: VPITAR; ISSN: 0042-8833

DOCUMENT TYPE: Journal

LANGUAGE: Russian

AB Thermally treated **tetracycline** [60-54-8], natural **tetracycline**, or penicillin [1406-05-9] at 100, 20, or 100 mg/kg fed to rats for 10-20 days led to increased bile secretion and decreased bile and liver **cholesterol** [57-88-5] content but did not affect blood serum **cholesterol** when a 20% protein diet was given. A low protein (1.2%) diet led to increased bile **cholesterol** and cholic acid [81-25-4], but decreased liver **cholesterol**. In both groups, free bile salts increased in bile and glycine and taurine **conjugates** decreased, especially with the low-protein diet.

=> s **cholesterol** bound to adraimycin

152831 **CHOLESTEROL**

755 **CHOLESTEROLS**

152985 **CHOLESTEROL**

(**CHOLESTEROL** OR **CHOLESTEROLS**)

379125 **BOUND**

11095 **BOUNDS**

387905 **BOUND**

(**BOUND** OR **BOUNDS**)

1 **ADRAIMYCIN**

L18 0 **CHOLESTEROL** **BOUND** **TO** **ADRAIMYCIN**

(**CHOLESTEROL** (W) **BOUND** (1W) **ADRAIMYCIN**)

=> s **cholesterol** and **adriamycin** complex

152831 **CHOLESTEROL**

755 **CHOLESTEROLS**

152985 **CHOLESTEROL**

(**CHOLESTEROL** OR **CHOLESTEROLS**)

9939 **ADRIAMYCIN**

16 **ADRIAMYCINS**

9941 **ADRIAMYCIN**

(**ADRIAMYCIN** OR **ADRIAMYCINS**)

1188143 **COMPLEX**

681062 **COMPLEXES**

1464520 **COMPLEX**

(**COMPLEX** OR **COMPLEXES**)

139 **ADRIAMYCIN** **COMPLEX**

(**ADRIAMYCIN** (W) **COMPLEX**)

L19 2 **CHOLESTEROL** **AND** **ADRIAMYCIN** **COMPLEX**

=> d L19 1-2 ibib,abs

L19 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1996:548157 CAPLUS

DOCUMENT NUMBER: 125:257076
 TITLE: Hydrogel nanoparticle formed by self-assembly of hydrophobized polysaccharide. Stabilization of adriamycin by complexation
 AUTHOR(S): Akiyoshi, Kazunari; Taniguchi, Ikuo; Fukui, Hiroki; Sunamoto, Junzo
 CORPORATE SOURCE: Dep. Synthetic Chem. Biol. Chem., University Kyoto, Kyoto, 606, Japan
 SOURCE: European Journal of Pharmaceutics and Biopharmaceutics (1996), 42(4), 286-290
 CODEN: EJPBEL; ISSN: 0939-6411
 PUBLISHER: Wissenschaftliche Verlagsgesellschaft
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB Hydrogel nanoparticles of **cholesterol**-bearing pullulan (CHP) after self-aggregation and complexing the antitumor drug adriamycin (I) were isolated by ultrafiltration to remove free uncomplexed I. The chemical stability of I was improved by complexation. Dissociation of I from the complex was slow, and >70% of I still remained in the complex after 7 days at 25 ° C and pH 7.4. The in vitro cytotoxicity of I against utero-cervical carcinoma cells was diminished by complexation.

L19 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 1996:522320 CAPLUS
 DOCUMENT NUMBER: 125:308905
 TITLE: Hydrogel nanoparticle of cell-specific amphiphilic polysaccharide
 AUTHOR(S): Taniguchi, I.; Akiyoshi, K.; Sunamoto, J.
 CORPORATE SOURCE: Graduate school of Engineering, Kyoto University, Kyoto, 606-01, Japan
 SOURCE: Proceedings of the International Symposium on Controlled Release of Bioactive Materials (1996), 23rd, 635-636
 CODEN: PCRMEY; ISSN: 1022-0178
 PUBLISHER: Controlled Release Society, Inc.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB The complexation of adriamycin with the hydrogel nanoparticle of hydrophobized **cholesterol**-bearing pullulan (CHP) self aggregates is described. The synthesis and characterization of cell-specific hydrophobized polymer are also described. Under the controlled condition, the cytotoxicity of adriamycin decreased upon the complexation. The diminished cytotoxicity of complexed adriamycin will be improved by modification of CHP with a cell-specific saccharide determinant, which makes receptor-mediated cell uptake possible.

=> d his

(FILE 'HOME' ENTERED AT 07:56:14 ON 25 MAR 2005)

FILE 'CAPLUS' ENTERED AT 07:56:44 ON 25 MAR 2005

L1 0 S ADRIAMYCIN CHOLESTEROL CONJUGATE
 L2 0 S TETRACYCLINE CHOLESTEROL CONJUGATE
 L3 118 S CHOLESTEROL CONJUGATES
 L4 9941 S ADRIAMYCIN
 L5 1 S L3 AND L4
 L6 23768 S TETRACYCLINE
 L7 0 S L3 AND L6
 L8 0 S CHOLESTEROL CONJUGATE AND TETRACYCLINE AND LIPOSOME
 L9 73944 S LDL OR LIPOSOME
 L10 133 S CHOLESTEROL CONJUGATE
 L11 9945 S ADRIAMYCIN OR TERTRACYCLINE
 L12 1 S L10 AND L11

```

L13      152985 S CHOLESTEROL
L14      9941 S ADRIAMYCIN
L15      92633 S CONJUGATE
L16      13 S L13 AND L14 AND L15
L17      2 S L13 AND TETRACYCLINE AND L15
L18      0 S CHOLESTEROL BOUND TO ADRAIMYCIN
L19      2 S CHOLESTEROL AND ADRIAMYCIN COMPLEX

```

```

=> s tetracycline and cholesterol complex
      22527 TETRACYCLINE
      4198 TETRACYCLINES
      23768 TETRACYCLINE
            (TETRACYCLINE OR TETRACYCLINES)
      152831 CHOLESTEROL
      755 CHOLESTEROLS
      152985 CHOLESTEROL
            (CHOLESTEROL OR CHOLESTEROLS)
      1188143 COMPLEX
      681062 COMPLEXES
      1464520 COMPLEX
            (COMPLEX OR COMPLEXES)
      469 CHOLESTEROL COMPLEX
            (CHOLESTEROL (W) COMPLEX)
L20      0 TETRACYCLINE AND CHOLESTEROL COMPLEX

```

```

=> tetracycline and cholestrol fomation
TETRACYCLINE IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

```

```

=> s tetracycline and cholestrol compound
      22527 TETRACYCLINE
      4198 TETRACYCLINES
      23768 TETRACYCLINE
            (TETRACYCLINE OR TETRACYCLINES)
      116 CHOLESTROL
      93516 COMPOUND
      792405 COMPOUNDS
      873953 COMPOUND
            (COMPOUND OR COMPOUNDS)
      1046326 COMPD
      1610396 COMPDS
      2282540 COMPD
            (COMPD OR COMPDS)
      2663091 COMPOUND
            (COMPOUND OR COMPD)
      0 CHOLESTROL COMPOUND
            (CHOLESTROL (W) COMPOUND)
L21      0 TETRACYCLINE AND CHOLESTROL COMPOUND

```

```

=> s tetracycline and cholestrol conjugate formation
      22527 TETRACYCLINE
      4198 TETRACYCLINES
      23768 TETRACYCLINE
            (TETRACYCLINE OR TETRACYCLINES)
      116 CHOLESTROL
      60060 CONJUGATE
      53041 CONJUGATES
      92633 CONJUGATE
            (CONJUGATE OR CONJUGATES)
      2543863 FORMATION
      52103 FORMATIONS
      2573231 FORMATION

```

(FORMATION OR FORMATIONS)

0 CHOLESTROL CONJUGATE FORMATION

(CHOLESTROL (W) CONJUGATE (W) FORMATION)

L22

0 TETRACYCLINE AND CHOLESTROL CONJUGATE FORMATION